Adelaide, Australia, 28 November 2018 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today reported its sales for the 4 months to 31 October 2018 to shareholders at the Company Annual General Meeting.

Highlights included:

- Group sales increased by 27% to $24.7 million (17% in constant currency)
- Sales growth for Ellex iTrack™ of 38% (26% in constant currency) in the USA, resulting from expanded sales and marketing initiatives. The Company’s iTrack™ surgical system is a canal-based, restorative minimally invasive glaucoma surgery (MIGS) device, which has been shown to effectively reduce intraocular pressure in cases of both mild-moderate and severe glaucoma. It has also been shown to effectively reduce the medication burden in cases of controlled glaucoma.
- Sales growth of the Company’s patented Ellex 2RT® Retinal Rejuvenation Therapy to $0.6 million this year compared with $0.1 million last year. This follows the positive 36-month results of the LEAD multi-centre clinical trial, announced on 21 September 2018. 2RT® is a world-first treatment which enables physicians to intervene during the early stage of age-related macular degeneration (AMD), before vision has been compromised. AMD is the leading cause of blindness in the developed world.

CEO Tom Spurling commented: “As a result of our significant investment in sales and marketing, our sales so far for this year are the largest in the history of the Company. Our growth has been driven by our strong global position in devices for glaucoma therapy with the Ellex iTrack™ surgical system and Ellex Tango™/Tango Reflex™ SLT laser platforms. This is a large market and growth will continue. We expect this growth to be materially augmented in the medium term by our Ellex 2RT® nanopulse laser for intermediate AMD. This represents the largest growth opportunity for our business.”

ABOUT ELLEX

Ellex designs, develops, manufactures and sells innovative product that help eye surgeons around the world to effectively and efficiently treat eye disease. Ellex is a
world leader in this field. Headquartered in Adelaide, Australia, Ellex has ophthalmic lasers and devices that treat glaucoma, retinal disease primarily caused by diabetes, secondary cataract and vitreous opacities, as well as age-related macular degeneration. Manufacturing is carried out in Adelaide, Australia and Fremont, California. Sales and service directly to eye surgeons is conducted via subsidiary offices in Minneapolis, Lyon, Berlin and Tokyo. A network of more than 50 distribution partners around the world services other markets.

For additional information about Ellex and its products, please visit

www.ellex.com

For further information on Ellex please contact:

Tom Spurling
CEO, Ellex
3 Second Avenue, Mawson Lakes, SA 5095
W +61 8 7074 8293 | M +61 417 818 658
tspurling@ellex.com

Dr. Tom Duthy
Investor Relations, Ellex
3 Second Avenue, Mawson Lakes, SA 5095
M +61 402 493 727
tduthy@ellex.com